Clinical Trial Update: A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer [Phase 1]

View source ↗

Summary

A Phase 1, open-label trial evaluating Belzupacap Sarotalocan (AU-011) for non-muscle-invasive bladder cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Belzupacap Sarotalocan

Snippet

Sponsor: Aura Biosciences | Conditions: Non-muscle-invasive Bladder Cancer, NMIBC | Phase 1 | Status: RECRUITING